Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID

@article{GarcaPrez2020SuccessfulPD,
  title={Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID},
  author={Laura Garc{\'i}a-P{\'e}rez and Marja van Eggermond and Lieke van Roon and Sandra A Vloemans and Martijn Cordes and Axel Schambach and Michael Rothe and Dagmar Berghuis and Chantal Lagresle-Peyrou and Marina Cavazzana and Fang Zhang and Adrian James Thrasher and Daniela C F Salvatori and Pauline Meij and Anna Villa and Jacques J.M. van Dongen and Jaap Jan Zwaginga and Mirjam van der Burg and H Bobby Gaspar and Arjan C. Lankester and Frank J. T. Staal and Karin Pike-Overzet},
  journal={Molecular Therapy. Methods \& Clinical Development},
  year={2020},
  volume={17},
  pages={666 - 682}
}

Figures from this paper

Preclinical Development of Autologous Hematopoietic Stem Cell-Based Gene Therapy for Immune Deficiencies: A Journey from Mouse Cage to Bed Side
TLDR
This review will address several different challenges in the development of gene therapy for immune deficiencies using Recombinase-activating gene 1 (RAG1) SCID as an example and discuss product development, proof-of-concept, and final release steps to the clinic.
Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency
TLDR
The transplantation of autologous gene corrected hematopoietic precursors and the use of non-genotoxic conditioning will open a new era, offering a cure to an increasing number of RAG patients regardless of donor availability and severity of clinical conditions.
Retroviral gene therapy in Germany with a view on previous experience and future perspectives
TLDR
Research groups in Germany made, and continue to make, important contributions to the development of gene therapy, including design of vectors and transduction protocols for improved cell modification, methods to assess gene therapy vector efficacy and safety, as well as in the design and conduction of clinical gene therapy trials.
Gene Therapy for Primary Immunodeficiency
TLDR
Key developments in the gene therapy landscape for primary immune deficiency are reviewed, from an experimental therapy where clinical efficacy was marred by adverse events, to a commercialized product with enhanced safety and efficacy.
Therapy Development by Genome Editing of Hematopoietic Stem Cells
TLDR
An overview of recent progress in the field of HSC genome editing as treatment for inherited disorders is given and technical hurdles that need to be overcome en route to clinical translation are discussed and advances that may facilitate routine application beyond the most common disorders are indicated.
Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning.
The transformative potential of HSC gene therapy as a genetic medicine.
TLDR
The rationale for targeting HSCs, the approaches that have been used to date for delivering therapeutic genes to these cells, and the latest technological breakthroughs in manufacturing and vector design are reviewed.
Genomic Engineering in Human Hematopoietic Stem Cells: Hype or Hope?
TLDR
The challenges of researching and developing a novel genetic engineering therapy for monogenic blood and immune system disorders are discussed and many obstacles still remain to be overcome before gene editing in HSCs for gene correction purposes can be applied clinically.
Gene therapy for primary immunodeficiencies
TLDR
HSC GT for PID shows great promise, but requires a unique approach for each disease and carries risks, notably insertional mutagenesis from gamma‐retroviral gene addition approaches and possible off‐target toxicities from gene‐editing techniques.
A Novel Branched DNA-Based Flowcytometric Method for Single-Cell Characterization of Gene Therapy Products and Expression of Therapeutic Genes
TLDR
A single cell-based method is introduced that allows to unmask cellular heterogeneity in the GT product, even when antibodies are not available, and is suitable for all therapeutic genes for which antibodies areNot available or too cumbersome for routine flow cytometry.
...
1
2
...

References

SHOWING 1-10 OF 66 REFERENCES
Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer
TLDR
The functional reconstitution of the B- as well as the T-cell compartment provides proof-of-principle for therapeutic RAG1 gene transfer in Rag1−/− mice using lentiviral SIN vectors.
Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity.
TLDR
It is demonstrated that correction of RAG-1 deficiency can be achieved by gene therapy in immunodeficient mice but that human application would require the use of self-inactivated vector to decrease the risk of lymphoproliferative diseases.
Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34+ cells isolated from Artemis or RAG1-deficient patients.
TLDR
It is reported that lentiviral gene-corrected BM CD34(+) cells sustain human B-cell differentiation following injection into non-obese diabetic/SCID (NOD-SCID) mice previously infused with anti-interleukin-2 receptor beta chain monoclonal antibody.
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
TLDR
A gene therapy trial for SCID-X1 was initiated, based on the use of complementary DNA containing a defective gammac Moloney retrovirus-derived vector and ex vivo infection of CD34+ cells, which provided full correction of disease phenotype and clinical benefit.
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects.
TLDR
The efficacy of LV gene transfer in correcting both the immunological and metabolic phenotypes of ADA-SCID is demonstrated and supports the future clinical use of this approach.
Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells.
TLDR
Transplantation of Artemis-transduced HSCs into irradiated Art(-/-) mice restored a stable and functional T- and cell repertoire that was comparable to that of control mice, and provides a basis for supporting the gene therapy approach in Artemis-deficient SCID.
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
TLDR
Gene transfer into HSCs is an effective treatment for SCID, although potentially limited by the risk of insertional mutagenesis, andGene-dense regions, promoters, and transcriptionally active genes were preferred retroviral integrations sites (RISs) both in preinfusion transduced CD34(+) cells and in vivo after gene therapy.
Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.
TLDR
The reduced mutagenic potential conferred by SIN vector configurations and alternative non-LTR-based regulatory elements, together with proven efficacy in correction of cellular defects provides an important platform for development of the next phase of clinical trials for SCID-X1.
Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1.
TLDR
If data of safety are confirmed over the long term, gene therapy for SCID-X1 appears to be an equal, if not superior, alternative to haploidentical HSCT.
...
1
2
3
4
5
...